We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

President to Sign Food and Drug Administration Safety and Innovation Act: Summary of Certain Key Provisions

09 July 2012

Health Alert

President Obama is expected to soon sign into law the Food and Drug Administration Safety and Innovation Act (FDASIA). When signed, FDASIA will reauthorize for another five years the Prescription Drug User Fee Act (PDUFA V) and the various related user fee agreements between the drug and device industries and the Food and Drug Administration (FDA). FDASIA includes provisions related to drugs, devices, generic drugs, and biosimilar biological products. The following is a summary of certain key provisions pertaining to innovator and, where specified, generic drugs and biosimilar biological products.

Read: "President to sign Food and Drug Administration Safety and Innovation Act: Summary of certain key provisions"

The team

Loading data